Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
46 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Program
On WRAL at 6: Hundreds of millions overbudget, WRAL Investigates delays in a Medicaid upgrade costing taxpayers and impacting patients
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
31.94
+0.32 (+1.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veracyte Inc
< Previous
1
2
3
4
5
6
Next >
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
August 26, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Second Quarter 2024 Financial Results
August 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
July 17, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
June 03, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
May 22, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in Upcoming Investor Conferences
May 15, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces First Quarter 2024 Financial Results
May 07, 2024
From
Veracyte, Inc.
Via
Business Wire
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
May 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
April 22, 2024
From
Veracyte, Inc.
Via
Business Wire
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
April 22, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
April 16, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
February 27, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
February 22, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
February 21, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 08, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Completes Acquisition of C2i Genomics
February 06, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
January 08, 2024
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
December 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
November 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
November 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Third Quarter 2023 Financial Results
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Stephens Annual Investment Conference
November 02, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
October 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
October 17, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
October 12, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
October 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
September 28, 2023
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.